Fields SM - Search Results

1

Phase I study with the DNA sequence-specific agent adozelesin.

Burris HA, Dieras VC, Tunca M, Earhart RH, Eckardt JR, Rodriguez GI, Shaffer DS, Fields SM, Campbell E, Schaaf L, Kasunic D, Von Hoff DD. Burris HA, et al. Among authors: fields sm. Anticancer Drugs. 1997 Jul;8(6):588-96. doi: 10.1097/00001813-199707000-00006. Anticancer Drugs. 1997. PMID: 9300573 Clinical Trial.

2

A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion.

Rodriguez GI, Kuhn JG, Weiss G, De La Cruz P, New P, Fields SM, Eckardt JR, Campbell L, Clark GM, Hilsenbeck SG, Von Hoff DD. Rodriguez GI, et al. Among authors: fields sm. Invest New Drugs. 1998;16(1):57-67. doi: 10.1023/a:1006003718255. Invest New Drugs. 1998. PMID: 9740545 Clinical Trial.

3

A phase II trial of DaunoXome, liposome-encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colon.

Eckardt JR, Campbell E, Burris HA, Weiss GR, Rodriguez GI, Fields SM, Thurman AM, Peacock NW, Cobb P, Rothenberg ML, et al. Eckardt JR, et al. Among authors: fields sm. Am J Clin Oncol. 1994 Dec;17(6):498-501. doi: 10.1097/00000421-199412000-00009. Am J Clin Oncol. 1994. PMID: 7977168 Clinical Trial.

4

Topoisomerase I inhibitors. An overview of the camptothecin analogs.

Burris HA 3rd, Fields SM. Burris HA 3rd, et al. Among authors: fields sm. Hematol Oncol Clin North Am. 1994 Apr;8(2):333-55. Hematol Oncol Clin North Am. 1994. PMID: 8040144 Review.

5

Preclinical and phase I trials of topoisomerase I inhibitors.

Von Hoff DD, Burris HA 3rd, Eckardt J, Rothenberg M, Fields SM, Chen SF, Kuhn JG. Von Hoff DD, et al. Among authors: fields sm. Cancer Chemother Pharmacol. 1994;34 Suppl:S41-5. doi: 10.1007/BF00684862. Cancer Chemother Pharmacol. 1994. PMID: 8070026 Clinical Trial.

6

A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies.

Shaffer DW, Smith LS, Burris HA, Clark GM, Eckardt JR, Fields SM, Weiss GR, Rinaldi DA, Bowen KJ, Kuhn JG, et al. Shaffer DW, et al. Among authors: fields sm. Cancer Res. 1993 Dec 15;53(24):5929-33. Cancer Res. 1993. PMID: 8261405 Clinical Trial.

7

New anticancer agents.

Weiss GR, Burris 3rd HA, Eckardt JR, Eckhardt SG, Fields SM, O'Rourke T, Rodriguez GI, Rothenberg ML, Valley AJ. Weiss GR, et al. Among authors: fields sm. Cancer Chemother Biol Response Modif. 1996;16:132-67. Cancer Chemother Biol Response Modif. 1996. PMID: 8639381 Review. No abstract available.

8

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.

Rinaldi DA, Burris HA, Dorr FA, Woodworth JR, Kuhn JG, Eckardt JR, Rodriguez G, Corso SW, Fields SM, Langley C, et al. Rinaldi DA, et al. Among authors: fields sm. J Clin Oncol. 1995 Nov;13(11):2842-50. doi: 10.1200/JCO.1995.13.11.2842. J Clin Oncol. 1995. PMID: 7595747 Clinical Trial.

9

Local soft tissue toxicity following cisplatin extravasation.

Fields S, Koeller J, Topper RL, Guritz G, Von Hoff D. Fields S, et al. J Natl Cancer Inst. 1990 Oct 17;82(20):1649-50. doi: 10.1093/jnci/82.20.1649. J Natl Cancer Inst. 1990. PMID: 2145441 No abstract available.

10

Idarubicin: a second-generation anthracycline.

Fields SM, Koeller JM. Fields SM, et al. DICP. 1991 May;25(5):505-17. doi: 10.1177/106002809102500511. DICP. 1991. PMID: 2068836 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

38 results

Search Page

Filters